Drug intelligence / Profile preview

AAV.EpoR76E

Development stage
Preclinical
Lead developer
University of Iowa
Modality
Gene Therapies, Recombinant Proteins and Enzymes
Administration
Intramuscular
01

Overview

**AAV.EpoR76E is a gene therapy consisting of an adeno-associated viral (AAV) vector encoding a modified form of erythropoietin, EpoR76E, in which the arginine at position 76 is replaced by glutamate. EpoR76E retains neuroprotective and neurotrophic activities but lacks erythropoietic (blood-forming) activity, reducing risk of increased hematocrit and related side effects. The therapy is delivered via intramuscular injection and yields sustained systemic expression of EpoR76E. It has been shown in preclinical models to prevent cognitive decline, neuronal loss, synaptic protein loss, and amyloid-β accumulation in Alzheimer's disease models, and also to protect dopaminergic neurons in Parkinson’s disease models and retinal ganglion cells in glaucoma models.**[1][5]

Other names
AAV-EpoR76EAAV-EpoR-76EAAV-EpoR 76EAAV2/5.CMV.EpoR76E
02

Targets

INSRR (Insulin receptor-related receptor)Erythropoietin Receptor

Beyond the preview

Go deeper on AAV.EpoR76E.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AAV.EpoR76E.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call